OSE Immunotherapeutics Provides Update on Ongoing Proceedings Ahead of Shareholders’ Annual General Meeting of September 30, 2025 NANTES, France, September 8, 2025, 6p.m. CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces that, following today’s hearing before the Nantes Commercial Court under the accelerated procedure (procédure dite “à bref délai”), the Court has taken under advisement the matter concerning the regularity of the declaration of the concerted action by a group of min ...